PsoriasisPhase 3NCT00293930
A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
A Phase 3 study testing Tacrolimus in people with Psoriasis, run by Astellas Pharma Inc at 32 sites in 2 countries.
Trial summary
A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Psoriasis
- What is being tested?
- Tacrolimus
- How many people
- 645 participants
- Where
- 32 sitesin 2 countries
- Study dates
- Start not givento Nov 2006
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Clinical diagnosis of plaque psoriasis
Who cannot join
- Skin disorder other than plaque psoriasis in the areas to be treated.
- Disease on only elbows, knees, and scalp
Trial locations and contacts
32 sites in 2 countries.
32 sites in 2 countries
United States26 sites
Study site
Bryan, Texas, 77802
Study site
Burlington, Vermont, 05401
Study site
Cincinnati, Ohio, 45219
Study site
Dallas, Texas, 75230
Study site
Dayton, Washington, 99328
Study site
Evansville, Indiana, 47713
Study site
Galveston, Texas, 77555
Study site
Hot Springs, Arkansas, 71913
Study site
Iowa City, Iowa, 52242
Study site
Longmont, Colorado, 80501
Study site
Lynchburg, Virginia, 24501
Study site
Madison, Wisconsin, 53719
Study site
Miami, Florida, 33175
Study site
Nashville, Tennessee, 37203
Study site
New Haven, Connecticut, 06511
Study site
New York, New York, 10029
Study site
Newnan, Georgia, 30263
Study site
Philadelphia, Pennsylvania, 19104
Study site
Portland, Oregon, 97210
Study site
Rochester, New York, 14623
Study site
San Diego, California, 92117
Study site
San Francisco, California, 94118
Study site
South Bend, Indiana, 46617
Study site
St Louis, Missouri, 63117
Study site
Washington D.C., District of Columbia, 20010
Study site
Winston-Salem, North Carolina, 27157
Canada6 sites
Study site
North Bay, Ontario, P1B 3Z7
Study site
Saskatoon, Saskatchewan, S7N 0W8
Study site
St. John's, Newfoundland and Labrador, A1B 4S8
Study site
Waterloo, Ontario, N2J 1C4
Study site
Windsor, Ontario, N8W 1E6
Study site
Winnipeg, Manitoba, R3C 0N2
About this study
A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis
- Conditions
- Psoriasis
- Being tested
- Tacrolimus
- Keywords
- Treatment Outcome, Tacrolimus, Safety, Psoriasis
- Medical subject headings
- Psoriasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TacrolimusDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2006 (estimated)
- Study completionNov 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PsoriasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 645 participants (actual)
Sponsor and investigators
- Lead sponsor
- Astellas Pharma Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Astellas Pharma US, Inc.
- Investigators
- J Rico, MD, Study director, Astellas Pharma US, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00293930
- Sponsor's protocol ID
- 04-0-205
- Status last verified
- Dec 2007
- First submitted
- 16 Feb 2006
- Last updated
- 24 Dec 2007
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Dec 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
- ClinicalTrials.gov ID
- NCT00293930
- Acronym / sponsor ID
- 04-0-205
- Conditions
- Psoriasis
- Keywords
- Treatment Outcome, Tacrolimus, Safety, Psoriasis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 645 participants (actual)
- Lead sponsor
- Astellas Pharma IncIndustry (pharma, biotech, devices)
- Collaborators
- Astellas Pharma US, Inc.
- Study completion
- Nov 2006 (actual)
- First posted
- 20 Feb 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Clinical diagnosis of plaque psoriasis
Key exclusion criteria (2 listed)
- Skin disorder other than plaque psoriasis in the areas to be treated.
- Disease on only elbows, knees, and scalp
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tacrolimus | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Dec 2007.
Related trials for Psoriasis
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
Recruiting
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Rhumatoid Arthisis, Spondyloarthritis (SA)
Active, not recruitingPhase 2
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
RecruitingPhase 1
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Psoriasis, Ankylosing Spondylitis
RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Psoriatic Arthritis, Axial Spondyloarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
J Rico, MD study director
Astellas Pharma US, Inc.
32 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tacrolimus in people with Psoriasis, run by Astellas Pharma Inc at 32 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Dec 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 32 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2007.